Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of China.
Research Institute of Nephrology, Zhengzhou University, Zhengzhou, 450052, People's Republic of China.
Mol Biol Rep. 2022 Aug;49(8):7709-7718. doi: 10.1007/s11033-022-07588-7. Epub 2022 Jun 13.
The transition from acute kidney injury (AKI) to chronic kidney disease (CKD) is extremely complex. Incomplete renal tubule repair, inflammation, and endoplasmic reticulum (ER) stress all play major roles. AKI activates ER stress, and the sensor protein inositol-requiring kinase-1 (IRE1) mediates inflammation by promoting the phosphorylation of C-jun NH2-terminal kinase (JNK). The interleukin-6/signal transducer and activator of transcription 3 (IL-6/STAT3) signaling pathway is associated with the secretion of renal extracellular matrix (ECM) and fibrosis. It remains unclear whether these signaling pathways play a role in the AKI-CKD transition.
In this study, a mouse model of ischemia-reperfusion (I/R) with bilateral renal artery clipping was used. IRE1 or JNK inhibitors were also injected to confirm their roles in the AKI-CKD transition. The renal function of the mice was determined by observing the pathology of the renal tubules and glomeruli through electron microscopy, immunohistochemistry, western blotting and quantitative real-time PCR.
I/R stimulates ER stress and the IRE1/JNK pathway in the renal tubules in a short period of time, leading to continuous inflammation. Long-term I/R injury activates the STAT3 pathway in the glomeruli, activates mesangial cells proliferation, causes secretion of large amounts of glomerular ECM, and promotes glomerular sclerosis. This damage to the renal tubules and glomeruli is significantly reduced in I/R model mice pretreated with IRE1 or JNK inhibitors.
These findings suggested that the IRE1/JNK pathway regulates the inflammatory cytokines caused by AKI and continues to activate the STAT3 pathway and production of ECM in the glomeruli at late stages, suggesting the feasibility of targeted therapy for the AKI-CKD transition.
从急性肾损伤 (AKI) 向慢性肾脏病 (CKD) 的转变极其复杂。不完全肾小管修复、炎症和内质网 (ER) 应激都起着重要作用。AKI 激活 ER 应激,感应蛋白肌醇需求激酶-1 (IRE1) 通过促进 C-Jun N 末端激酶 (JNK) 的磷酸化来介导炎症。白细胞介素-6/信号转导和转录激活因子 3 (IL-6/STAT3) 信号通路与肾脏细胞外基质 (ECM) 的分泌和纤维化有关。这些信号通路是否在 AKI-CKD 转变中起作用尚不清楚。
在本研究中,使用双侧肾动脉夹闭的缺血再灌注 (I/R) 小鼠模型。还注射了 IRE1 或 JNK 抑制剂以确认它们在 AKI-CKD 转变中的作用。通过电镜观察肾小管和肾小球的病理变化、免疫组织化学、Western blot 和定量实时 PCR 来确定小鼠的肾功能。
I/R 在短时间内刺激肾小管中的 ER 应激和 IRE1/JNK 途径,导致持续的炎症。长期 I/R 损伤激活肾小球中的 STAT3 途径,激活系膜细胞增殖,导致大量肾小球 ECM 分泌,并促进肾小球硬化。在预先用 IRE1 或 JNK 抑制剂处理的 I/R 模型小鼠中,这种对肾小管和肾小球的损伤明显减少。
这些发现表明,IRE1/JNK 途径调节 AKI 引起的炎症细胞因子,并在晚期继续激活 STAT3 途径和肾小球 ECM 的产生,提示针对 AKI-CKD 转变的靶向治疗具有可行性。